Drug Discovery: Gene targets for Human African Trypanosomiasis (HAT)

Between 2008 and 2012, I engaged in wet lab work attempting to identify small compounds that, based on in vitro assays, inhibit a key metabolic enzyme in Trypansome parasites responsible Human African Trypanosomiasis (HAT) and, as such, could constitute a putative therapeutic target for HAT. 

The work comprised Four stages:

  1. Developing a luminescent assay that would place the recombinant enzyme target front and centre in an in vitro assay, enabling screening of small molecule(s). Preceeding the assay, work was put in to expressing and purifying active recombinant target. A poster succintly describes key stages in this development and optimisation. 
  2. Validation of the assay using compounds with tried and tested efficacy against the protein target. This is illustrated in another conference poster.
  3. Optimisation of the assay to improve specificity and sensitivity.
  4. Screening caches of compounds that had been predicted to bind to the target protein by in silico modelling. A series of conference posters were used to present this story, including this one. 

The over all procedural pipeline from de novo assay to compound screen is tracked in working portfolios linked to my weebly web site. Beyond this empirical bench work, two publications came to press, describing the two  stages of this project, namely:

  1. Initial validation of the assay using known inhibitors of the recombinant enzyme target. 
  2. Subsequent assay optimisation to improve sensitivity and specificity.

Proof of principle paper

A paper in which compounds identified by in silico modelling were evaluated for actual REL 1 binding efficacy in vitro  This work performed by me at Edinburgh University,  circa 2008-2012.

AI Summary of REL 1 Assay development paper

Assay development paper paper

A paper in which the basic FRET assay, validated as specific opposite, is further tweaked to improve sensitivity & S:N. This work was performed by me at Edinburgh University, circa 2008-2012.

AI Summary of REL 1 Assay development paper

Development of a FRET Assay for Anti HAT drug discovery

Work associated with my time @ Edinburgh University, circa 2008-2012, in which I was part of an ambitious project whose aim was to indentify small molecule inhibitors of a key enzyme and putative target protein for Human African Trypanosomiasis (HAT) called RNA Editing Ligase 1 (REL1). My personal contribution was as follows:

  • To express a recombinant form of the target protein enzyme.

  • To Develop a high through put FRET drug screening assay, based on this enzyme.  

  • To utilise this assay In Vitro to screen small compound libraries and identify inhibitors of REL 1 by FRET.

  • To evaluate the efficacy of identified inhibitors by implementing a "killing fields" In Vivo cytotoxic assay against live Trypanosome parasites using Alamar Blue. 

  • The work was highly successful on my part and culminated in two key publications and numerous conference posters. 

Posters & project reports showing key stages in the development of a FRET based in vitro assay for high through put screening of small compound libraries in order to identify antagonists of recombinant REL 1 and thus putative anti HAT chemo therapeutics